Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

2.5.1.18: glutathione transferase

This is an abbreviated version!
For detailed information about glutathione transferase, go to the full flat file.

Word Map on EC 2.5.1.18

Reaction

RX
+
glutathione
=
HX
+
R-S-glutathione

Synonyms

2-hydroxychromene-2-carboxylic acid isomerase, 26GST, adGSTD4-4, agGSTe2, allergen Der p 2, allergen Der p 8, alpha class glutathione transferase, Alpha class GST, alpha GST, alpha-class glutathione transferase, asGST5.5, AtGSTF2, AtuGSTH1-1, BaeAB, beta-etherase, bmGSTD, BphK, CgGSTM1, CgGSTM2, cGST, Chi class GST, Chi GST, class mu glutathione S-transferase, delta class glutathione transferase, delta-class glutathione S-transferase, Delta-class glutathione transferase, EC 1.8.6.1, EC 2.5.1.12, EC 2.5.1.13, EC 2.5.1.14, EC 4.4.1.7, EGST, epsilon class GST, Epsilon glutathione S-transferase, Epsilon glutathione transferase, Epsilon GST, epsilon-class glutathione S-transferase, epsilon-class glutathione transferase, GHR, glutathione S-alkyl transferase, glutathione S-aralkyltransferase, glutathione S-aryltransferase, glutathione S-transferase, glutathione S-transferase 2, glutathione S-transferase A1-1, glutathione S-transferase A3-3, glutathione S-transferase AdFSTD3-3, glutathione S-transferase I, glutathione S-transferase omega 1, glutathione S-transferase omega 2, glutathione S-transferase P1-1, glutathione S-transferase pi, glutathione S-transferase Pi-1, glutathione S-transferase X, glutathione transferase, glutathione transferase A1-1, glutathione transferase A4-4, glutathione transferase M1-1, glutathione transferase M2-2, glutathione transferase Omega 3S, glutathione transferase omega-1, glutathione transferase P1-1, glutathione transferase Pi, glutathione transferase T1-1, glutathione transferase zeta, glutathione transferase zeta 1, glutathione transferase Zeta 1-1, glutathione transferase zeta1-1, glutathione transferase-like protein, glutathione-S-transferas, glutathione-S-transferase, glutathione-S-transferase pi, glutathione-transferase, GmGSTU4-4, GSH S-transferase, GSH transferase, GSH transferase homologue, GSH-S transferase rho, GSHTase-P, GST, GST A1-1, GST A2-2, GST A3-3, GST A4-4, GST adgstD4-4, GST alpha, GST Delta 2, GST I, GST II, GST III, GST IV, GST M1-1, GST M2-2, GST M4-4, GST M5-5, GST mu, GST O1-1, GST P1-1, GST pi, GST T1-1, GST Tau, GST Tau19, GST Z1-1, GST-1, GST-2, GST-26, GST-3, GST-Acr, GST-OCX-32, GST-T, GST-theta, GST1, GST1b, GST2, GST20, GST3, GST4, GST5, GST5118, GST7, GST83044, Gsta, GSTA1, GSTA1-1, GSTA2-2, GSTA3, GSTA3-3, GSTA4, GSTA4-4, GSTA4L, GSTA5, GSTA5-5, GSTalpha1, GSTD, GSTD1, GSTD10, GSTd14, GSTD2, GSTD4, GSTD4-4, GSTE1, GSTE2, GSTE3, GSTE4, GSTE5, GSTE6, GSTE7, GSTE8, GSTF12-1, GSTF12-2, GSTF3, GSTF5, GSTF9, GSTFuA1, GSTk, GSTK1, GSTL1, GSTL2, GSTL3, Gstm, GSTm09, GSTM1, GSTM1-1, GSTM2, GSTM2-2, GSTM3, GSTM3-3, GSTM4, GSTM4-4, GSTM5, GSTM5-5, GSTmu, GSTO, GSTO1, GSTO1-1, GSTO2, GSTO2-2, GstO2A, GstO2B, GSTO3, GSTO3S, GSTO4, GSTO7, GSTP, GSTP 1-1, GSTP-1, GSTP1, GSTP1-1, Gstr1, GSTrho, GSTS, GSTS1, GSTS1-1, GSTS2, GSTS3, GSTT, GSTT1, GSTT1-1, Gstt1a, GSTT2, GSTT2-2, GSTT2B-2B, GSTT4, GSTT4L, GSTU1, GSTU10, GSTU10-10, GSTU11, GSTU12, GSTU13, GSTU13-1, GSTU14, GSTU16, GSTU17, GSTU18, GSTU19, GSTU2, GSTU2-2, GSTU21, GSTU24, GSTU24-1, GSTU25, GSTU26, GSTU28, GSTU3, GSTU4, GSTU45, GSTU5, GSTU6, GSTU7, GSTU8, GSTU9, GSTZ, Gstz1, GSTZ1-1, GTT1.2, HCCA isomerase, Hematopoietic prostaglandin D synthase, hGSTA-3, hGSTA1-1, hGSTZ1-1, kappa class glutathione transferase, kappa class GSH transferase, Kappa class GST, KKSG9, lambda glutathione transferase, MAAI, MGST1, MGST2, MGST3, Mgst3a, Mgst3b, microsomal glutathione transferase 1, microsomal glutathione transferase-1, More, mtMGST1, mu class glutathione S-transferase, Mu class GST, mu glutathione transferase, Mu GST, mu-class glutathione S-transferase, mu-class glutathione S-transferase1, Mu-class GST, Mu-GST, nu-class glutathione transferase, Omega class GST, omega glutathione S-transferase, omega glutathione transferase, omega-class glutathione S-transferase, omega-class glutathione S-transferase 2, pGSTA1, phi class glutathione transferase, Pi class GST, pm-GSTR1, PmGST, PtGSTU1, PvGSTF1-1, PvGSTU2-2, PvGSTU3-3, rho class glutathione S-transferase, rho-GST, RX: glutathione R-transferase, RX:glutathione R-transferase, S-(hydroxyalkyl)glutathione lyase, Saro_2873/Saro_2872, selenium-containing glutathione transferase zeta1-1, seleno-hGSTZ1-1, SGST26.5, sigma class glutathione transferase, Sigma class GST, sigma glutathione S-transferase, sigma-class glutathione S-transferase, sigma-class GST, SIGST, Sj26GST, sjGST, sll1545, ssGST3, ssGST5, tau class glutathione S-transferase, tau class glutathione transferase, tau class GST, tau class GSTU4-4, TDR1, theta class glutathione S-transferase, theta class glutathione transferase T1-1, theta class GST, theta-class glutathione transferase, thiol-dependent reductase I, Ure2p mutant A122C, Ure2pB1, Xi class glutathione transferase, Ya-GST, YghU, zeta class glutathione S-transferase, Zeta class GST

ECTree

     2 Transferases
         2.5 Transferring alkyl or aryl groups, other than methyl groups
             2.5.1 Transferring alkyl or aryl groups, other than methyl groups (only sub-subclass identified to date)
                2.5.1.18 glutathione transferase

Inhibitors

Inhibitors on EC 2.5.1.18 - glutathione transferase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(+)-catechin hydrate
-
inhibition of isozymes GST M1-1 and M2-2
(+)-limonene oxide
about 85% inhibition at 0.1 mM
(-)-limonene oxide
about 15% inhibition at 0.1 mM
(17-chloro-3b-hydroxy-androsta-5,16-diene)-succinyl-glutathione
-
-
(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol
-
a coumaroflavan from Treculia africana, 26% total inhibition at 0.033 mM
(2Z)-2-[(4-methoxyphenyl)carbonyl]-3-(2,3,4-trimethoxyphenyl)prop-2-enoic acid
-
-
(2Z)-2-[(4-methylphenyl)carbonyl]-3-(2,3,4-trimethoxyphenyl)prop-2-enoic acid
-
-
(2Z)-2-[(4-methylphenyl)carbonyl]-3-phenylprop-2-enoic acid
-
8.1% inhibition at 0.02 mM
(2Z)-3-(1,3-benzodioxol-5-yl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid
-
10% inhibition at 0.02 mM
(2Z)-3-(1,3-benzodioxol-5-yl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
9.6% inhibition at 0.02 mM
(2Z)-3-(2-methylphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
9.3% inhibition at 0.02 mM
(2Z)-3-(3,4-dihydroxyphenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-(3,4-dihydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-(3-hydroxyphenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid
-
6.6% inhibition at 0.02 mM
(2Z)-3-(3-hydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
13.9% inhibition at 0.02 mM
(2Z)-3-(3-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
19.0% inhibition at 0.02 mM
(2Z)-3-(4-chlorophenyl)-2-[(4-methoxyphenyl)carbonyl]prop-2-enoic acid
-
14.4% inhibition at 0.02 mM
(2Z)-3-(4-chlorophenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
14.4% inhibition at 0.02 mM
(2Z)-3-(4-fluorophenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-(4-hydroxy-3-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
8.8% inhibition at 0.02 mM
(2Z)-3-(4-hydroxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
12.5% inhibition at 0.02 mM
(2Z)-3-(4-methoxyphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-(4-methylphenyl)-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
-
(2Z)-3-[4-(dimethylamino)phenyl]-2-[(4-methylphenyl)carbonyl]prop-2-enoic acid
-
9.3% inhibition at 0.02 mM
(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)methanesulfonyl fluoride
-
-
(4S,6Z,10Z,11aS)-4-ethoxy-6-(hydroxymethyl)-3-methylidene-10-propoxy-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one
-
a sesquiterpene lactone from Dicoma anomala collected from Namibia, 75% total inhibition at 0.033 mM
(E)-2-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)ethene-1-sulfonyl fluoride
-
-
(E)-N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)but-2-enamide
-
-
(R)-carvone
about 8% inhibition at 0.1 mM
(S)-2-amino-4-cyanobutyric acid
-
-
1,2-dichloro-4-nitrobenzene
-
1 mM, 53.3% inhibition of wild-type enzyme, 40.4% of mutant enzyme H144A, 42.4% of mutant enzyme V147A, 54.3% of mutant enzyme V147L, 35.9% of mutant enzyme R96A
1,3-Bis-(2-chloroethyl)-1-nitrosourea
-
competitive
1,4-pentadiene-3-one
1,7-dihydroxyanthracen-9(10H)-one
-
a xanthone from Mammea africana, 21% total inhibition at 0.033 mM
1-(4-benzylpiperidin-1-yl)prop-2-en-1-one
-
1-(4-phenylpiperidin-1-yl)prop-2-en-1-one
-
1-Amino-4-{[4-({4-chloro-6-[(2-sulfophenyl)amino]-1,3,5-triazin-2-yl}amino)-3-sulfophenyl]amino}-9,10-dioxo-9,10-dihydro-2-anthracenesulfonic acid
1-chloro-2,3-dinitrobenzene
-
-
1-chloro-2,4-dinitrobenzene
1-methyl-2-[((2-nitrobenzyl)sulfonyl)]-1H-pyrrole
-
44.3% inhibition at 0.1 mM
1-methyl-2-[(2-nitrobenzyl)sulfanyl]-1H-pyrrole
-
-
1-naphthol
-
-
11(13)germacratrien-12,6-olide
55% inhibition at 0.033 mM
2,3,4,5-tetrahydroxy-6H-benzo[7]annulen-6-one
-
50% inhibition at 0.0052 mM
2,3,5,6-tetrachloro-1,4-benzoquinone
-
i.e. TCBQ, inhibition of GSTA1-2 and GSTA1-1 by 70-80%, and GSTA2-2 by 25%, binds to cysteine residues of the enzyme, e.g. Cys17 of GSTA1-1, via a first reversible step to covalent binding, overview, Kitz-Wilson inactivation model
2,4,6-trichloroanisole
about 5% inhibition at 0.1 mM
2,4,6-Trinitrobenzenesulfonate
-
-
2,5-dibenzylidenecyclopentanone
2,6-dibenzylidenecyclohexanone
2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,7-diol
85% inhibition at 0.1 mM
2-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)ethane-1-sulfonyl fluoride
-
-
2-(4-chlorophenyl)-6-[(fluorosulfonyl)oxy]quinoline-4-carboxylic acid
-
2-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)imidazole
-
-
2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-((1E)-[4-(trifluoromethyl)phenyl]methylene)aniline
-
68.4% inhibition at 0.1 mM
2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-(4-nitrophenyl)methylene]aniline
-
90.0% inhibition at 0.1 mM
2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-(phenyl)methylene]aniline
-
30.2% inhibition at 0.1 mM
2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)-N-[(1E)-1H-pyrrol-2-ylmethylene]aniline
-
36.0% inhibition at 0.1 mM
2-butanethiol
about 2% inhibition at 0.01 mM
2-chloro-5-((cyanomethyl)amino)-N,N-dimethylbenzenesulfonamide
-
-
2-chloro-N,N-dimethyl-5 -(oxiran-2-ylmethyl) -benzenesulfonamide
-
-
2-chloro-N,N-dimethyl-5-(oxiran-2-yl)benzenesulfonamide
-
-
2-chloro-N,N-dimethyl-5-(vinylsulfonamido)-benzenesulfonamide
-
2-chloro-N-(2-(N,N-dimethylsulfamoyl)-[1,1'-biphenyl]-4-yl)-acetamide
-
-
2-chloro-N-(3-(morpholinosulfonyl)-4-(trifluoromethyl)phenyl)-acetamide
-
-
2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-(trifluoromethoxy)-phenyl)acetamide
-
-
2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-(trifluoromethyl)-phenyl)acetamide
-
-
2-chloro-N-(3-(N,N-dimethylsulfamoyl)-4-iodophenyl)-acetamide
-
-
2-chloro-N-(4-(2-hydroxyphenyl)thiazol-2-yl)-N-((3-methylisoxazol-5-yl)methyl)acetamide
-
2-chloro-N-(4-chloro-3-(morpholinosulfonyl)phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-propanamide
-
-
2-chloro-N-(4-chloro-3-(N-((tetrahydrofuran-2-yl)methyl)-sulfamoyl)phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(2-hydroxyethyl)-N-methylsulfamoyl)phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(2-hydroxyethyl)sulfamoyl)phenyl)-acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(2-methoxyethyl)-N-methylsulfamoyl)phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(2-methoxyethyl)sulfamoyl)phenyl)-acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(3-methoxypropyl)-N-methylsulfamoyl)phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(3-methoxypropyl)sulfamoyl)phenyl)-acetamide
-
-
2-chloro-N-(4-chloro-3-(N-(tetrahydrofuran-3-yl)sulfamoyl)-phenyl)acetamide
-
-
2-chloro-N-(4-chloro-3-(N-isopropylsulfamoyl)phenyl)-acetamide
-
-
2-chloro-N-(4-chloro-3-(N-methylsulfamoyl)phenyl)acetamide
-
-
2-chloro-N-methyl-N-[(1-phenyl-1H-pyrazol-3-yl)methyl]acetamide
i.e. C4-10
2-chloro-N-[2-(cyclohexylamino)-2-oxo-1-(pyridin-2-yl)ethyl]-N-(3-fluorophenyl)acetamide
i.e. KT53
2-chloro-N-[4-chloro-3-(N,N-dimethylsulfamoyl)phenyl]acetamide
2-fluoro-N-[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl]-5-(oxiran-2-yl)benzene-1-sulfonamide
i.e. CRID2
2-hydroxyanthracen-9(10H)-one
-
a xanthone Mammea from africana, 38% total inhibition at 0.033 mM
2-mercaptoethanol
-
50% inhibition at 4 mM
2-methyl-1,4-naphthoquinone
3.9% to 43.2% inhibition at 0.025 mM to 0.2 mM
2-[(1-methyl-1H-pyrrol-2-ylsulfonyl)methyl]aniline
-
28.0% inhibition at 0.1 mM
2-[4-[(2E)-3-(2-bromophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
noncompetitive inhibition
2-[4-[(2E)-3-(2-chlorophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
noncompetitive inhibition
2-[4-[(2E)-3-(3-bromophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
-
2-[4-[(2E)-3-(3-chlorophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
-
2-[4-[(2E)-3-(4-bromophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
competitive inhibition
2-[4-[(2E)-3-(4-chlorophenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
noncompetitive inhibition
2-[4-[(2E)-3-(4-methylphenyl)prop-2-enoyl]phenyl]-3a,4,7,7a-tetrahydro-1H-4,7-methanoisoindole-1,3(2H)-dione
Coturnix sp.
-
noncompetitive inhibition
3,3',5,5'-tetrabromophenolphthalein
-
-
3-(3,4-dihydroxybenzoyl)-4-hydroxy-8-methyl-1,5,7-tris(3-methylbut-2-en-1-yl)-8-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione
-
a benzophenone Garcinia smeathmannii, 41% total inhibition at 0.033 mM
3-(3,4-dihydroxybenzoyl)-4-hydroxy-8-methyl-5,7-bis(3-methylbut-2-enyl)-8-(4-methylpent-3-enyl)bicyclo[3.3.1]nonane-2,9-dione
95% inhibition at 0.033 mM
3-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)propane-1-sulfonyl fluoride
-
-
3-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)propionic acid
-
-
3-chloro-N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-propenamide
-
-
3-ethyl-2-oxo-3,3a,7a,9b-tetrahydro-2H,4aH-1,4,5-trioxadicyclopenta[a,hi]indene-7-carboxylic acid
-
an iridoid from Plumeeria rubra, 51% total inhibition at 0.033 mM
4,4'-dichlorodiphenyltrichloroethane
-
-
4-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)butanol
-
-
4-(acryloylamino)-N-(5-[[5-([5-[(2-carbamimidamidoethyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)-1-methyl-1H-pyrrole-2-carboxamide
-
a brostallicin derivative, the debrominated derivative of brostallicin is almost completely ineffective as an inhibitor of GSTP1-1
4-nitrobenzyl chloride
4-nitrophenethyl bromide
-
0.1 mM, 40.1% inhibition of wild-type enzyme, 23.6% of mutant enzyme H144A, 19.5% of mutant enzyme V147A, 31.4% of mutant enzyme V147L, 27.3% of mutant enzyme R96A
4-[(2-bromoacryloyl)amino]-N-(5-[[5-([5-[(2-carbamimidamidoethyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)-1-methyl-1H-pyrrole-2-carboxamide
-
i.e. brostallicin, mixed-type inhibition, inhibits GSTP1-1 and GSTM2-2, thereby being much more efficient in inhibiting GSTM2-2 than in inhibiting GSTP1-1. Brostallicin sensitivity for brostallicin is higher in cells overexpressing either the GST-pi or the GST-mu gene
4-[3-(5,5-dimethyl-4-oxo-4,5-dihydrofuran-2-yl)-3-hydroxybutoxy]-7H-furo[3,2-g]chromen-7-one
5,7-dihydroxy-6-(2-hydroxybutanoyl)-8-(3-methylbut-2-en-1-yl)-4-propyl-2H-chromen-2-one
-
a coumarin from Mammea africana, 33% total inhibition at 0.033 mM
5,8-dihydroxy-1-(hydroxymethyl)naphtho[2,3-c]furan-4,9-dione
5,8-dihydroxy-1-methylnaphtho[2,3-c]furan-4,9-dione
85% inhibition at 0.1 mM
5-(chloromethyl)-3-oxo-3H-spiro[[2]benzofuran-1,9'-xanthene]-3',6'-diyl diacetate
i.e. CMFDA
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-(4-chlorobenzyl)-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-(4-fluorophenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-(4-methoxyphenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-(4-nitrobenzyl)-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-methyl-1,2,4-oxadiazol
-
-
5-[2,3-dichloro-4-(2-methylene-1-oxobutyl)phenoxymethyl]-3-phenyl-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-chlorobenzyl)-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-fluorophenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-hydroxyphenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-nitrobenzyl)-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-methyl-1,2,4-oxadiazol
-
-
5-[2,3-dimethyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-phenyl-1,2,4-oxadiazol
-
-
5-[3-bromo-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-fluorophenyl)-1,2,4-oxadiazol
-
-
5-[3-bromo-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol
-
-
5-[3-bromo-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-methyl-1,2,4-oxadiazol
-
-
5-[3-bromo-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-phenyl-1,2,4-oxadiazol
-
-
5-[3-chloro-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-fluorophenyl)-1,2,4-oxadiazol
-
-
5-[3-chloro-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol
-
-
5-[3-chloro-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-methyl-1,2,4-oxadiazol
-
-
5-[3-chloro-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-phenyl-1,2,4-oxadiazol
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-fluorophenyl)-1,2,4-oxadiazol
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-hydroxyphenyl)-1,2,4-oxadiazol
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-nitrobenzyl)-1,2,4-oxadiazol
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-(4-trifluoromethylphenyl)-1,2,4-oxadiazol
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-methyl-1,2,4-oxadiazole
-
-
5-[3-methyl-4-(2-methylene-1-oxopropyl)phenoxymethyl]-3-phenyl-1,2,4-oxadiazole
-
-
6-(7-nitro-2,1,3-benzoxadiazol-4-ylamino)hexanol
-
-
6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol
-
-
6-butanoyl-5,7-dihydroxy-4-phenyl-2H-chromen-2-one
-
a coumarin from Mammea africana, 23% total inhibition at 0.033 mM
7-nitro-2,1,3-benzoxadiazole derivatives
-
non-GSH peptidomimetic compounds, suicide inhibitors of the enzyme, binding structure and mechanism, overview, the compounds show strong GST inhibition and accumulation in tumor cells avoiding the extrusion mechanisms mediated by the multidrug resistance protein pumps
-
abamectin
Al3+
-
68% inhibition at 100 mg/kg for male rats, 24% inhibition at 172.5 mg/kg for female rats
alachlor
albendazol
-
17.87% inhibition at 1 mM
albendazole
alizarin
allyl-isothiocyanate
about 30% inhibition at 0.01 mM
alpha-endosulfan
-
about 55% residual activity at 0.1 mM
alpha-tocopherol
-
significant inhibition
ascorbate
-
ascorbate enhances the inhibitory effects of SH reagents, overview, inactivation of total cytosolic GST activity from liver by the oxygen radical-generating system Cu2+/ascorbate, two mechanisms: ROS-induced oxidation and non-specific Cu2+ binding to protein thiol groups
AsO42-
-
Atrazine
-
about 95% residual activity at 0.1 mM
benastatin A
-
IC50: 0.00041 mM
bendiocarb
benzene hexachloride
-
-
Berberine
complete inhibition at 0.1 mM
beta-endosulfan
-
about 90% residual activity at 0.1 mM
beta-ionone
about 15% inhibition at 0.1 mM
bifenthrin
-
7.27% inhibition of isoform GSTd10 at 0.05 mM
bile acid
-
41.78% inhibition at 1 mM
bilirubin
bithionol
bongkrekic acid
-
-
brassylic acid
-
-
Bromocresol green
-
-
bromosulfophthalein
Bromosulphthalein
bromothymol blue
-
-
butanol
-
50% inactivation at 5%
Caffeine
about 25% inhibition at 0.01 mM
cantharidic acid
cantharidin
-
-
carbendazim
-
about 80% residual activity at 0.1 mM
carbosulfan
-
in vivo inhibition
chalcone
-
50% inhibition at 0.045 mM
chlorambucil
very poor inhibitor of the enzyme in contrast to ethacrynic acid
chlorfenapyr
chlorophenol red
-
-
chlorotriphenyltin
chlorpyrifos
chrysin
about 30% inhibition at 0.1 mM
Cibacron blue
cinnamaldehyde
about 60% inhibition at 0.1 mM
citral
about 25% inhibition at 0.1 mM
Cl-
-
inhibits reaction with 1-chloro-2,4-dinitrobenzene with IC50: 0.12 mM. No inhibitory effect on the reaction with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole
clofentezine
-
28.05% inhibition of isoform GSTd14 at 0.05 mM and 27.68% inhibition of isoform GSTm09 at 0.05 mM
clothianidin
-
about 85% residual activity at 0.1 mM
coumarin
about 17% inhibition at 0.01 mM
Cr6+
-
58% inhibition at 10 mg/l
cumene hydroperoxide
-
2.5 mM, 43.3% inhibition of wild-type enzyme, 27% of mutant enzyme H144A, 50.6% of mutant enzyme V147A, 41.5% of mutant enzyme V147L, 48.1% of mutant enzyme R96A
curcumin
cyclohexanone
about 3% inhibition at 0.1 mM
cypermethrin
-
in vivo inhibition
daidzein
-
inhibition of isozymes GST A1-1, M1-1, and P1-1
delphinidin chloride
-
strong inhibition
deltamethrin
denatonium benzoate
about 10% inhibition at 0. 1 mM
desmedipham
-
about 62% residual activity at 0.1 mM
diazinon
dibutyltin
-
-
Dichloroacetic acid
i.e. DC, used to treat lactic acidosis and has also been proposed as a novel anticancer agent is both a substrate and a mechanism-based inactivator of GSTZ1-1. Treatment with DCA progressively inactivates GSTZ1-1 and increases the elimination half-life of subsequent doses of DCA. recombinant GSTZ1*A protein is relatively resistant to DCA mediated inactivation when compared with the other isoforms
dichlorvos
dicoumarol
-
-
dieldrin
-
a potent reversible inhibitor toward hGSTA1-1, mixed-type inhibition, dieldrin binds specifically to the enzyme presumably at a position that partially overlaps with both the G- and H-site, a site distinct from binding of spiromesifen, binding structure overview
difheberan
-
about 47% residual activity at 0.1 mM
-
Diflubenzuron
-
about 45% residual activity at 0.1 mM
Digitonin
about 20% inhibition at 0.01 mM
Dimethyl sulfide
about 5% inhibition at 0.1 mM
dinitrophenyl-glutathione
-
-
dithiothreitol
DTT
-
50% inhibition at 10 mM
ellagic acid
endosulfan
-
about 73% residual activity at 0.1 mM
epiandrosterone-aspartyl-glutathione
-
-
epiandrosterone-succinyl-glutathione
-
-
epichlorohydrin
-
3 mM, competitive
epiphyllocoumarin
95% inhibition at 0.1 mM
epoxiconazole
-
about 40% residual activity at 0.1 mM, complete inhibition at 0.2 mM
escin
about 10% inhibition at 0.1 mM
-
Ethacrynic acid
ethanol
-
inhibits the mu- and pi-class GST activities in vivo by 53% and 13%, respectively, in hepatocytes and the culture medium, the enzyme activity is increased in the cell medium, overview, the inhibitory effect is completely oe partially reversible by vitamin E or 4-methylpyrazole, respectively
ethyl 2-acrylamido-4-phenylthiazole-5-carboxylate
-
ethyl 2-acrylamido-4-phenylthiophene-3-carboxylate
-
ethyl 2-acrylamido-5-phenylthiophene-3-carboxylate
-
ethyl N-acryloyl-N-(4-phenylthiazol-2-yl)glycinate
-
Evan's blue
-
-
FeCl3
-
-
fenamidone
-
about 78% residual activity at 0.1 mM
fenhexamid
-
about 85% residual activity at 0.1 mM
fenitrothion
fenvalerate
-
-
ferriprotoporphyrin IX
-
in presence of glutathione, GST serves as ligand for parasitotoxic ferriprotoporphyrin IX with a high- and a low-affinity binding site, uncompetitive inhibition type, overview
ferulic acid
-
inhibition of isozyme GST M1-1
fisetin
60% inhibition at 0.1 mM
flavonol
about 20% inhibition at 0.01 mM
fludioxonil
-
about 81% residual activity at 0.1 mM
fluopyram
-
about 82% residual activity at 0.1 mM
fluorescein
-
-
fluoxastrobin
-
about 75% residual activity at 0.1 mM
gamma-Glu-Cys(Acm)-Gly
85.2% remaining activity at 0.0003 mM
gamma-Glu-Cys(t-buthio)-Gly
85.6% remaining activity at 0.0003 mM
gamma-Glu-Met-Gly
79.4% remaining activity at 0.0003 mM
gamma-Glu-Thi-Gly
67.4% remaining activity at 0.0003 mM
gamma-glutamyl-(c-methoxycarbonyl)-alpha-glutamylglycine
-
-
gamma-glutamyl-5-azanylidyne-L-norvalylglycine
-
-
gamma-glutamyl-L-threonylglycine
-
-
gamma-L-glutamyl-L-seryl-glycine
-
-
genistein
-
inhibition of isozymes GST M1-1 and M2-2
geraniol
about 3% inhibition at 0.1 mM
geranyl acetate
about 5% inhibition at 0.01 mM
geshoidin
85% inhibition at 0.1 mM
glutathione
Gly-Cys-Hyp
87.4% remaining activity at 0.0003 mM
GSSG
-
IC50: 2.0 mM for homodimeric enzyme, IC50: 2.6 mM for heterodimeric enzyme
guanidine hydrochloride
haematin
Hematin
hemin
Hexachlorophene
hexanoic acid
about 5% inhibition at 0.1 mM
hexyl glutathione
hexythiazox
-
11.21% inhibition of isoform GSTd14 at 0.05 mM and 12.94% inhibition of isoform GSTm09 at 0.05 mM
Hyp-Cys-Ala
98.7% remaining activity at 0.0003 mM
imidacloprid
Indocyanine green
indomethacin
iodoacetamide
-
IC50: 40 mM for homodimeric enzyme, 8.7 mM for heterodimeric enzyme
iodoacetate
iprodione
-
about 60% residual activity at 0.1 mM
K+
-
93.7% residual activity at 5 mM
kaempferol
KCl
-
IC50: 0.33 M for homodimeric enzyme, IC50: 0.18 M for heterodimeric enzyme
knipholone anthrone
95% inhibition at 0.1 mM
kresoxim-methyl
-
about 87% residual activity at 0.1 mM
L-g-glutamyl-S-[3-([5-[(5-[[5-([5-[(2-carbamimidamidoethyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]amino)-2-hydroxy-3-oxopropyl]-L-cysteinylglycine
-
a brostallicin derivative, inhibits GSTP1-1 and GSTM2-2
L-g-glutamyl-S-[3-([5-[(5-[[5-([5-[(2-carbamimidamidoethyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]carbamoyl)-1-methyl-1H-pyrrol-3-yl]carbamoyl]-1-methyl-1H-pyrrol-3-yl)carbamoyl]-1-methyl-1H-pyrrol-3-yl]amino)-3-oxo-2-(phosphonooxy)propyl]-L-cysteinylglycine
-
a brostallicin derivative, inhibits GSTP1-1 and GSTM2-2
L-gamma-glutamyl-S-(2-hydroxy-5-nitrophenyl)-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
L-gamma-glutamyl-S-[(17beta)-17-hydroxy-17-methyl-3-oxoandrost-4-en-4-yl]-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
L-gamma-glutamyl-S-[1-(3-chlorophenyl)-2-hydroxyethyl]-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
L-gamma-glutamyl-S-[2-(4-nitrophenyl)-2-oxoethyl]-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
L-gamma-glutamyl-S-[2-(6-oxocyclohex-1-en-1-yl)ethyl]-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
L-gamma-glutamyl-S-[3-[4-(carboxymethoxy)-2,3-dichlorophenyl]-3-oxopropyl]-L-cysteinylglycine
-
nonenzymatically synthesized GSH conjugate
lambda-cyhalothrin
limonene oxide
about 70% inhibition at 0.1 mM
lithocholate
-
50% inhibition at 0.1 mM
luteolin
about 16% inhibition at 0.01 mM
malathion
competitive
mercury acetate
-
50% inhibition at 28 nM
Mersalyl acid
-
-
mesityl oxide
about 5% inhibition at 0.1 mM
metalaxyl
-
about 61% residual activity at 0.1 mM
methyl (E)-4-((4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-amino)but-2-enoate
-
methyl N-acryloyl-N-(4-phenylthiazol-2-yl)glycinate
-
N-((1E)-[4-(dimethylamino)phenyl]methylene)-2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)aniline
-
78.9% inhibition at 0.1 mM
N-((3-methylisoxazol-5-yl )methyl)-N-(4-(4-chloro-2-hydroxylphenyl)thiazol-2-yl)acrylamide
-
N-((3-methylisoxazol-5-yl)methyl)-N-(4-(2-hydroxylphenyl)-thiazol-2-yl)acrylamide
-
N-((3-methylisoxazol-5-yl)methyl)-N-(4-(2-methoxyphenyl)-thiazol-2-yl)acrylamide
-
N-((3-methylisoxazol-5-yl)methyl)-N-(4-(4-fluoro-2-hydroxylphenyl)thiazol-2-yl)acrylamide
-
N-((3-methylisoxazol-5-yl)methyl)-N-(4-(4-trifluoromethylphenyl)thiazol-2-yl)acrylamide
-
N-((3-methylisoxazol-5-yl)methyl)-N-(4-phenylthiazol-2-yl)-acrylamide
-
N-(1-benzyl-1H-pyrazol-4-yl)acrylamide
-
N-(1-phenyl-1H-pyrazol-4-yl)acrylamide
-
N-(2-((2-morpholinoethyl)amino)-2-oxoethyl)-N-(4-phenylthiazol-2-yl)acrylamide
-
N-(2-(cyclohexylamino)-2-oxoethyl)-N-(4-phenylthiazol-2-yl)-acrylamide
-
N-(2-(oxetan-3-ylamino)-2-oxoethyl)-N-(4-phenylthiazol-2-yl)-acrylamide
-
N-(2-morpholino-2-oxoethyl)-N-(4-phenylthiazol-2-yl)-acrylamide
-
N-(4-(2-chlorophenyl)thiazol-2-yl)acrylamide
-
N-(4-(2-fluorophenyl)thiazol-2-yl)acrylamide
-
N-(4-(2-hydroxylphenyl)thiazol-2-yl)acrylamide
-
N-(4-(2-hydroxyphenyl)thiophen-2-yl)-N-((3-methylisoxazol-5-yl)methyl)acrylamide
-
N-(4-(2-methoxyphenyl)thiazol-2-yl)acrylamide
-
N-(4-(3,4-dioxylphenyl)thiazol-2-yl)acrylamide
-
N-(4-(3-chlorophenyl)thiazol-2-yl)acrylamide
-
N-(4-(4-chlorophenyl)thiazol-2-yl)acrylamide
-
N-(4-(4-hydroxylphenyl)thiazol-2-yl)acrylamide
-
N-(4-(4-methoxyphenyl)thiazol-2-yl)acrylamide
-
N-(4-(4-methylphenyl)thiazol-2-yl)acrylamide
-
N-(4-(4-trifluoromethylphenyl)thiazol-2-yl)acrylamide
-
N-(4-(naphthalen-2-yl)thiazol-2-yl)acrylamide
-
N-(4-bromo-3-(N,N-dimethylsulfamoyl)phenyl)-2-chloroacetamide
-
-
N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-2-cyanoacetamide
-
-
N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-2-fluoroacetamide
-
-
N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)-2-oxopropanamide
-
-
N-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)acrylamide
N-(4-phenyl-5-methyl-thiazol-2-yl)acrylamide
-
N-(4-phenylthiazol-2-yl)-N-(pyridin-3-ylmethyl)acrylamide
-
N-(4-phenylthiazol-2-yl)acrylamide
-
N-(5-phenylthiazol-2-yl)acrylamide
-
N-acetyl-p-benzoquinoneimine
concentration-dependent inhibition
N-acryloyl-N-(4-phenylthiazol-2-yl)glycine
-
N-benzyl-N-(4-phenylthiazol-2-yl)acrylamide
-
N-ethylmaleimide
N-[(1E)-(2-chlorophenyl)methylene]-2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)aniline
-
88.8% inhibition at 0.1 mM
N-[(1E)-(4-chlorophenyl)methylene]-2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)aniline
-
60.4% inhibition at 0.1 mM
N-[(1E)-(4-fluorophenyl)methylene]-2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)aniline
-
37.1% inhibition at 0.1 mM
N-[(1E)-(5-bromo-2-methoxyphenyl)methylene]-2-([(1-methyl-1H-pyrrol-2-yl)sulfonyl]methyl)aniline
-
646% inhibition at 0.1 mM
N-[3-[(chloroacetyl)(4-nitrophenyl)amino]propyl]-2,2,2-trifluoroacetamide
i.e. ML175
N1-(4-chloro-3-(N,N-dimethylsulfamoyl)phenyl)oxalamide
-
-
N5-[(1S)-2-[(carboxymethyl)amino]-1-(cyanomethyl)-2-oxoethyl]glutamine
-
-
Na+
-
81.7% residual activity at 5 mM
naphthalene oxide
-
0.09 mM, competitive
naringenin
42% inhibition at 0.1 mM
naringin
about 17% inhibition at 0.01 mM
NH4Cl
-
IC50: 0.2 M for homodimeric enzyme, IC50: 0.12 M for heterodimeric enzyme
Nicotine
about 16% inhibition at 0.01 mM
oxidized glutathione
-
-
p-nitrobenzylglutathione
-
papaverine
about 5% inhibition at 0.1 mM
paraoxon
paraxanthine
about 9% inhibition at 0.01 mM
permethrin
peroxynitrite
-
-
pGlu-Cys(Trt)-Gly
82.3% remaining activity at 0.0003 mM
phenethyl-isothiocyanate
about 25% inhibition at 0.01 mM
phenmedipham
-
about 63% residual activity at 0.1 mM
Phenol red
-
-
Phenolphthalein
-
-
Phenylglyoxal
-
-
phoxim
-
56% inhibition of isoform GST-1 at 0.1 mM, 14.8% inhibition of isoform GST-2 at 0.1 mM, 20.6% inhibition of isoform GST-3 at 0.1 mM
phthalein
-
-
picoxystrobin
-
about 58% residual activity at 0.1 mM
piperidine
about 15% inhibition at 0.1 mM
piroxamine
-
about 92% residual activity at 0.1 mM
prasterone-aspartyl-glutathione
-
-
prasterone-succinyl-glutathione
-
-
praziquantel
prinoidin
70% inhibition at 0.1 mM
propyl-isothiocyanate
42% inhibition at 0.01 mM
Prostaglandins
-
isozyme GST P1-1 forms covalent complexes with cyclopentenone prostaglandins, i.e. cyPG 15-deoxy-DELTA12,14-PGJ2 and biotinylated 15d-PGJ2, mass spectrometry analysis, overview, irreversible inhibition
-
prothioconazol
-
about 85% residual activity at 0.1 mM
protoporphyrin IX
pyraclostrobin
-
about 70% residual activity at 0.1 mM
pyridaben
-
25.84% inhibition of isoform GSTm09 at 0.05 mM
Pyridine
about 17% inhibition at 0.1 mM
pyrimethanil
-
about 80% residual activity at 0.1 mM
quercetin
Quinine
about 18% inhibition at 0.1 mM
resveratrol
-
inhibition of isozymes GST A2-2, M1-1, M2-2, and P1-1
Rose bengal
S-(2,4-dinitrophenyl)glutathione
S-(2,4-dinitrophenyl)GSH
-
-
S-(4-azidophenacryl)-glutathione
-
competitive inhibitor, 27% loss of activity after 5 min
S-(4-Bromobenzyl)glutathione
S-(p-nitrobenzyl)-glutathione
-
-
S-carvone
S-carvone inhibits 26% of the enzyme activity at 0.01 mM and 84% at 0.1 mM
S-glutathionyl-phenylacetophenone
-
S-glutationyl-thiodione
-
S-hexyl glutathione
S-hexyl-glutathione
S-hexyl-GSH
-
IC50: 0.0152 mM
S-hexylglutathione
S-methyl-GSH
S-Methylglutathione
-
competitive
S-phenylacetylglutathione
-
Sb3+
-
69% inhibition at 0.1 mM
SeO32-
-
20% inhibition at 0.1 mg/l
sinigrin hydrate
about 28% inhibition at 0.01 mM
Sodium dodecyl sulfate
-
denaturates irreversibly at 0.03 M
sodium oxide
-
about 50% residual activity at 0.1 mM
-
spirodichlofen
-
-
spiromesifen
-
a potent reversible inhibitor toward hGSTA1-1, mixed-type inhibition, spiromesifen binds specifically to the enzyme presumably at a position that partially overlaps with both the G- and H-site, a site distinct from binding of dieldrin, binding structure overview
strychnine
about 37% inhibition at 0.01 mM
sulfophenolphthalein
-
-
sulfophthalein
superoxide anion
-
generated by a Fe3+/ascorbate system, inhibits cytosolic GSTs and microsomal GSTs by 30% and 65%, respectively. Addition of 2 mM DTT fails to completely reverse microsomal GST inhibition elicited by Fe3+/ascorbate, recovering only about 10% of this activity, but it completely reverses the inhibitory effect of Fe3+/ascorbate on cytosolic GST activity
tangeretin
complete inhibition at 0.1 mM
Tannic acid
taurine
about 19% inhibition at 0.1 mM
teflubenzuron
-
about 62% residual activity at 0.1 mM
terbuthylazine
-
about 97% residual activity at 0.1 mM
tert-butyl N-acryloyl-N-(4-phenylthiazol-2-yl)glycinate
-
Theobromine
about 12% inhibition at 0.01 mM
theophylline
about 10% inhibition at 0.01 mM
thiamine hydrochloride
about 5% inhibition at 0.1 mM
thiazolidine
about 18% inhibition at 0.01 mM
Thiourea
-
-
Tic-Cys(Acm)-Gly
68.5% remaining activity at 0.0003 mM
Tic-Cys-Aib
80.1% remaining activity at 0.0003 mM
Tic-Cys-Sar
53% remaining activity at 0.0003 mM
tolclofos-methyl
-
about 55% residual activity at 0.1 mM
trans-2-hexen-1-al
about 23% inhibition at 0.1 mM
trans-2-nonenal
about 23% inhibition at 0.01 mM
trans-o-hydroxybenzylidene pyruvic acid
-
-
triadimenol
-
about 75% residual activity at 0.1 mM
tributyltin
Tributyltin acetate
tridiphane
-
-
Triethyltin bromide
trifloxystrobin
-
about 65% residual activity at 0.1 mM
triflumuron
-
about 70% residual activity at 0.1 mM
triphenylthin chloride
-
-
Triphenyltin
Triphenyltin chloride
Triton X-100
-
-
undecanedioic acid
-
-
Vanillin
vinclozolin
-
about 73% residual activity at 0.1 mM
vinylpyridine
-
weak
vitamin K
-
-
[(3aR,5R,7aR)-3a,5-dihydroxy-7a-methyloctahydro-1H-inden-1-one]-succinyl-glutathione
-
-
[(3aR,5S,7aR)-3a,5-dihydroxy-7a-methyloctahydro-1H-inden-1-one]-aspartyl-glutathione
-
-
[(3aR,5S,7aR)-3a,5-dihydroxy-7a-methyloctahydro-1H-inden-1-one]-succinyl-glutathione
-
-
additional information
-